bile duct cancer
FDA Approves Roche CDx Test for Use With Jazz Pharmaceuticals Drug in Biliary Tract Cancer
The approval is for a new indication for Roche's existing Pathway HER2 (4B5) test and is intended to identify patients with HER2-positive biliary tract cancer.
Foundation Medicine, Relay Therapeutics to Develop FoundationOne CDx for FGFR2 Inhibitor
The companion diagnostic would be used to identify patients with FGFR2 fusions and select rearrangements in cholangiocarcinoma.
FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx
Truseltiq is a new option for FGFR2 fusion-positive, locally advanced, or metastatic cholangiocarcinoma patients who have received prior treatment.
Incyte's Pemazyre, Foundation Medicine CDx Get FDA Approval for FGFR2-Mutated Bile Duct Cancer
The FDA approved the drug based on data on response rate but continued approval is contingent on the results of a randomized study showing a PFS and OS advantage.
Kephera Awarded $300K Grant to Develop Liver Fluke Infection Test
Long-term infection with the parasite, which is primarily found in Asia, can lead to a form of bile duct cancer called cholangiocarcinoma.